SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is surging as a short-seller retracted damaging allegations, sparking strong community discussion around a potential short squeeze and a significant rebound for the stock ahead of its upcoming earnings report.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending sharply lower following the FDA's Complete Response Letter for its RGX-121 gene therapy, citing concerns with trial design and a clinical hold linked to a potential tumor in a related program. The community is fiercely debating the severe impact on the company's immediate future and the broader gene therapy sector, while some highlight the continued value of other key pipeline assets.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending after its recent earnings report presented mixed results and conservative guidance, leading to a sharp market sell-off. Community discussion centers on whether the stock is oversold and fundamentally undervalued given its profitability, or if broader fintech sector headwinds and management's cautious outlook justify the decline.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending following a mixed earnings report where strong Q4 results were overshadowed by lower-than-expected Q1 guidance, leading to a significant stock decline. The community is sharply divided, debating whether the dip presents a buying opportunity or if concerns about declining active clients and AI's impact on the gig economy are valid.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl is trending as its stock plunged following the abrupt departures of its CFO and general counsel amid an ongoing accounting review, delayed filings, and a lowered outlook for fiscal 2026. The community is sharply divided between those calling it a "falling knife" and comparing it to past accounting scandals, and dip buyers who believe the sell-off is an "overreaction" given its revenue and stating no material impact to core financials is currently expected.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is currently trending as investors keenly await congressional decisions on ACA subsidies, which could significantly influence its future growth, alongside an upcoming earnings report. Sentiment among the community is polarized, with many bulls anticipating a rally on policy clarity and improved financials, while bears caution about continued losses and sector-wide pressures.

Silvercorp Metals, Inc. engages in the acquisition, exploration, development, and mining of mineral properties and Environmental, Social and Governance practices. It operates through Mining and Administrative segments. The Mining segment includes Henan Luoning, Guangdong, and others. Its products include Silverbearing lead and Zinc Concentrates.The Administrative segment focuses on Vancouver and Beijing. The company was founded by Rui Feng on October 31, 1991 and is headquartered in Vancouver, Canada.

Silvercorp Metals Inc

Silvercorp Metals Inc.

Silvercorp Metals Inc. is trending following a "blow out" earnings report that smashed estimates with strong financial performance and significant cash flow, sparking community discussions focused on the impressive beat and expectations for further guidance.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending with a notable sell-off after reporting mixed earnings and issuing a soft Q1 outlook, leading to strong community debate on whether market reaction is overdone. While some express concern over perceived "stabilization" in automotive and industrial markets, others point to the company's strategic focus on AI data center power and recent partnerships as potential long-term catalysts.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

AgomAb Therapeutics NV - ADR

AgomAb Therapeutics NV is trending as a new IPO with an extremely low float, fueling intense community discussion about its potential for a short squeeze and rapid price movement, while others anticipate a pullback after its initial run.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv ($FISV) is trending as investors eagerly await its upcoming earnings report, creating a stark community divide between bulls citing undervaluation and strong fundamentals, and bears fearing another significant drop. Many are drawing parallels to recent struggles in the fintech sector and notable declines from companies like PayPal, contributing to heightened options activity and uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MediciNova's (MNOV) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued a "buy" rating and set a $9.00 price objective on shares of MediciNova in a research note on Friday...

MediciNova (NASDAQ:MNOV) Share Price Crosses Above 200 Day Moving Average - Should You Sell?

MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving Average - Time to Sell...

MediciNova (NASDAQ:MNOV) Rating Increased to Strong-Buy at Lucid Cap Mkts

Lucid Cap Mkts upgraded shares of MediciNova to a "strong-buy" rating in a research note on Monday...

MediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving Average - What's Next?

MediciNova (NASDAQ:MNOV) Share Price Crosses Above 200-Day Moving Average - Time to Sell...

MediciNova, Inc. (NASDAQ:MNOV) Sees Large Decline in Short Interest

MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) was the target of a significant decline in short interest in December. As of December 15th, there was short interest totaling 282,769 shares, a...

MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average - Should You Sell?

MediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving Average - Here's Why...

MediciNova (NASDAQ:MNOV) Stock Price Passes Above Two Hundred Day Moving Average - Here's Why

MediciNova (NASDAQ:MNOV) Shares Pass Above 200 Day Moving Average - Here's What Happened...

MediciNova (NASDAQ:MNOV) Issues Earnings Results, Beats Estimates By $0.02 EPS

MediciNova (NASDAQ:MNOV - Get Free Report) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus...

<ul class="summary-bullets"><li>The newly published study showed that MediciNova’s compound tipelukast (MN-001) and its metabolite MN-002 helped the body clear cholesterol more effectively, a mechanism that could play a role in preventing artery plaque buildup.</li><li>The company said the findings build on earlier data from patients with fatty liver disease and high triglycerides, strengthening the case for the drug’s potential in metabolic and cardiovascular conditions.</li><li>On Stocktwits, retail traders described the after-hours move as a “monster” and said they were watching for a breakout above $2.50 with a “big green candle” in the next session.</li></ul>Shares of MediciNova Inc. jumped 85% in after-hours trading on Thursday after the biotechnology company said new research showed its experimental compound tipelukast (MN-001) and its metabolite MN-002 could offer a new therapeutic approach for atherosclerosis.The study, published in the Journal of Atherosclerosis and Thrombosis, found that MN-002 enhanced the body’s ability to remove cholesterol from immune cells by increasing the activity of transport proteins ABCA1 and ABCG1. The mechanism could help limit cholesterol buildup in arteries, a key factor in the development of cardiovascular disease.The research was conducted in collaboration with a Japanese academic group specializing in lipid and cholesterol metabolism. According to MediciNova, the findings suggest tipelukast may play a role in regulating cholesterol and lipid pathways, with potential applications in atherosclerosis, type 2 diabetes, and dyslipidemia.<h2 class="st-heading-2">Building On Earlier Clinical Results</h2>MediciNova said the findings add to previous clinical data showing improvements in cholesterol and triglyceride levels among patients with non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, particularly in those with diabetes.The company is nearing completion of enrollment for a Phase 2 randomized, double-blind, placebo-controlled study evaluating MN-001 in patients with hypertriglyceridemia, type 2 diabetes, and NAFLD.<h2 class="st-heading-2">Stocktwits Traders See Momentum Building</h2>On Stocktwits, retail sentiment for MediciNova was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:970/141;" src="https://news.stocktwits-cdn.com/mnov_ss_jpg_c4730fcad3.webp" alt="mnov ss.jpg" width="970" height="141"><figcaption>MNOV sentiment and message volume as of October 30 | Source: Stocktwits</figcaption></figure>One user described the move as a “monster” and said they were adding a small position in case the stock climbed further before the market opened.&nbsp;<stembedurl>https://stocktwits.com/makedatbread88/message/634417869</stembedurl>Another user noted that the next key level to watch was $2.50, adding that they were hoping to see a “big green candle” in the next session.<stembedurl>https://stocktwits.com/Targeted_Trading/message/634416145</stembedurl><a href="https://stocktwits.com/symbol/MNOV">MediciNova’s stock</a> has declined 43% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MediciNova’s stock (MNOV) has declined 43% so far in 2025. (Photo credit: Getty Images)

MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’ 

The newly published study showed that MediciNova’s compound tipelukast (MN-001) and its metabolite MN-002 helped the body clear cholesterol more effectively, a mechanism that could play a role in preventing artery plaque buildup.

Equity

&nbsp;The stock market rally stalled on Tuesday, with the S&amp;P 500 Index retreating from its record closing high of 6,001.35. The weakness could be due to traders taking profit off their recent gains and shifting to the sidelines ahead of some key Main Street data on inflation and retail sales.IT, real-estate and industrial stocks served as drags, while the strength in the consumer discretionary and financial spaces offset some of the weakness.As the market pauses, here’s a compilation of stocks retailers on the Stocktwits platform are most bullish and bearish about:Most BullishNeuronetics, Inc. ($STIM)Pennsylvania-based Neuronetics, a commercial-stage med-tech company has seen its shares plunge hard following its third-quarter earnings announcement. The loss per share of $0.44 grossly missed the consensus loss estimate of $0.23, and revenue of $18.53 million also trailed the $19.14 million.The stock plunged about 40% but retail is ‘extremely” bullish on the stock.Zscaler, Inc. ($ZS)Shares of Zscaler, a San Jose, California-based cybersecurity company, rose nearly 3% on&nbsp;Tuesday following an announcement regarding its “Zero Trust Segmentation” solution.&nbsp;This solution will “provide a more secure, agile and cost-effective means to connect users, devices, and workloads across and within globally distributed branches, factories, campuses, data centers, and public clouds,” the company said.Axsome Therapeutics, Inc. ($AXSM)New York-based Axsome, which focuses on central nervous system disorders, reported a double beat for the third quarter. The stock rose over 6% following the quarterly results. The company has an FDA decision date in late January for its migraine treatment candidate.&nbsp;“We expect a busy end to the year with several clinical catalysts anticipated, including a planned simultaneous release of topline results from the ongoing Phase 3 ADVANCE-2 and ACCORD-2 trials of AXS-05 in Alzheimer’s disease agitation in the fourth quarter,” said CEO Herriot Tabuteau.Bitcoin Depot, Inc. ($BTM)Atlanta, Georgia-based Bitcoin Depot provides users with simple and efficient ways to convert cash into Bitcoin ($BTC.X).&nbsp;The company’s shares are pulling back after Monday’s 54% jump but retail held on to its bullish bias.MediciNova, Inc. ($MNOV)La Jolla, California-based MediciNova, said it was notified by Sanofi ($SNY) that the Sanofi/Novartis AG ($NVS) litigation was settled. This provides for MediciNova receiving&nbsp;a certain amount of monetary damages through this settlement. MediciNova’s stock jumped following the news, triggering positive reaction from the retail crowd.Most BearishReviva Pharmaceuticals, Holdings, Inc. ($RVPH)Reviva, a late-stage&nbsp;pharma developing therapies in the areas of central nervous system, inflammatory and cardiometabolic diseases, announced a positive update on the enrollment for the ongoing 1-year open-label extension study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. The stock climbed about 33% on Tuesday but retail sentiment was at a rock bottom.Pagaya Technologies Ltd. ($PGY)Israel-based Pagaya, a provider of&nbsp;financial products and services, reported a loss for the third quarter, which was much wider than expected. The stock slumped over 35%. Some among the retailers called outt the company a “fraud.Aldeyra Therapeutics, Inc. ($ALDX)Lexington, Massachusetts-based Aldeyra is a biotech focusing on therapies for immune-mediated and metabolic diseases. The shares of the company plunged on Tuesday on just about average volume.&nbsp;Retailers on the Stocktwits platform fretted over poor data for its dry eye disease product candidate.&nbsp;Quantum-Si Inc. ($QSI)Protein sequencing company Quantum-Si’s shares plunged over 22% on Tuesday after the&nbsp; Branford, Connecticut-based company reported its third-quarter results.ViaSat, Inc. ($VSAT)Shares of Carlsbad, California-based ViaSat have been ailing ever since the satellite telecommunications reported its financial results for the fiscal year 2025 second-quarter results last Thursday. This, in turn, has dented retail sentiment.&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/euphoric-run-of-tesla-stock-catalyzed-by-election-result-stalled/cJ40dh1ROF">Tesla Stock’s Post-Election Rally Stalls But Analyst Talks Up His $500 Bull-Case Scenario: Retail Mood Stays Sou</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

A slew of biopharma stocks made big moves on Tuesday. 

10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday

Earnings largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.

MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Medicinova Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

MNOV
Medicinova Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MNOV News

MNOVMedicinova Inc